Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

4 Apr 2011 07:00

RNS Number : 1957E
ViaLogy PLC
04 April 2011
 



VIALOGY PLC ("VIALOGY" or "THE COMPANY")

 

TRADING UPDATE

QUARTERLY BUSINESS HIGHLIGHTS

 

London, April 4, 2011, ViaLogy PLC (LSE: VIY). ViaLogy reports the following business highlights for the quarter ending March 31.

ViaLogy has made significant progress in its strategy of winning major global oil and gas industry clients, applying QuantumRD in major onshore and offshore exploration and development projects, and positioning QuantumRD as an accepted risk reduction technology in the industry's mainstream. Having completed technical discussions and successfully concluded technology demonstration projects, detailed contract proposals have been requested and submitted both to a Fortune Global 500 E&P firm and a major National OilCompany. ViaLogy's work should complement and enhance industry tools, and the Board's intention is that it should also establish both price and revenue levels for its QuantumRD technology. Successful application of the technology could spell capital expenditure savings as well as more accurate drilling locations for the two clients. Contract timing will depend in part on government approval for work in national lease properties and specific contract terms and conditions.

Under a previously announced contract ViaLogy has analysis underway on seismic data provided for a prospect owned by a supermajor company.

ViaLogy has also launched a development project to extend the use of Quantum Resonance Interferometry (QRI), its fundamental patented IP, to the shale gas microseismic market. This rapidly developing market segment utilises seismic data to monitor subsurface activity during the fracturing process, a key step in the production of natural gas. Vast natural gas deposits in the US and elsewhere will depend upon microseismic analysis for extraction. ViaLogy believes its weak signal detection technology, and its ability to detect subtle fractures, can both reduce costs and facilitate production. Natural gas is projected to account for 24% of the global energy supply by 2020 and shale gas is expected to account for over 64% of the natural gas in the US by 2020.  ViaLogy is pursuing this work in conjunction with an international oilfield services company.

 

ViaLogy recently received notice that its QRI technology patent has been officially allowed in China, an important step in protecting ViaLogy's future market position in that country. Patents have already been issued in the US and Europe.

In an update to the January announcement reporting a successful well based on QuantumRD analysis, initial production has been established at over 100 barrels per day. Hydrocarbon zone depths and porosities conform to ViaLogy's projections.

CEO Robert Dean commented, "ViaLogy continues to make impressive progress as measured against our ambitious business objectives. For over a year most of our limited resources have been focused on further development of the technology, on demonstrating its use as a risk-reduction tool in the context of an accepted industry workflow suite, and its application and efficacy in tough exploration prospects by clients whose recognition will be critical to business growth. Pre-contract work for our prospective clients has contributed to a real spirit of partnership. Also, the importance of natural gas as a current and future energy source has convinced us that we have to devote effort to enter this adjacent market for our technology." 

For further information contact:

 

ViaLogy PLC

 

Terry Bond, Chairman - UK & Europe +44 (0) 1235 834 734

 

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

 

Mark Percy / Catherine Leftley, Corporate Finance +44 (0) 207 107 8000

 

Katie Ratner / Jeremy Stephenson, Corporate Broking +44 (0) 207 107 8000

 

 

About ViaLogy:

ViaLogy provides reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas customers based on proprietary, patented active signal processing technology. ViaLogy's QuantumRD platform assists clients in de-risking prospects over a broad range of subsurface lithologies and complex stratigraphies to generate drilling targets, position offsets and enhance recovery.

 

ViaLogy's core technology rapidly and accurately detects weak signals buried in high noise background and clutter, and is applicable to active/passive seismic, electromagnetic and magneto telluric data. By exploiting normally disregarded noise variations induced by changes in porosity, fluid presence and permeability across the formation, and adding computer-designed noise to the data, ViaLogy is able to amplify subtle noise variations to enhance areal and depth resolution in complex lithologies that are not achievable through conventional means. For more information on ViaLogy, visit www.vialogy.com.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTKXLFBFZFLBBV
Date   Source Headline
15th May 20187:00 amRNSYear-end Trading Update and £2.5m Fundraising
30th Apr 20184:00 pmRNSNotice of Trading Update
29th Mar 20187:00 amRNSPremaitha to attend industry conferences in APAC
26th Mar 20187:00 amRNSUpdate on UK patent infringement claim
16th Feb 20187:00 amRNSPremaitha secures market entry into Egypt
14th Feb 201810:25 amRNSHolding(s) in Company
12th Feb 20187:00 amRNSThermo Fisher - issue of warrants
6th Feb 20187:00 amRNSPremaitha to attend key conferences in Middle East
5th Feb 20187:00 amRNSPremaitha's IONA test approved for sale in Brazil
24th Jan 20187:00 amRNSUK High Court grants right to appeal
22nd Jan 20187:00 amRNSSecured loan facility agreement with Thermo Fisher
29th Dec 20177:00 amRNSHalf Year Results
11th Dec 20177:00 amRNSPremaitha secures four further laboratories in EU
1st Dec 20179:40 amRNSPremaitha CEO Wins Outstanding Contribution Award
27th Nov 20177:00 amRNSMiddle East laboratory network expansion
23rd Nov 20177:00 amRNSPremaitha signs new partner in East Asia
21st Nov 201710:47 amRNSLitigation First Instance Judgment
30th Oct 201710:08 amRNSGrant of Share Options
24th Oct 20173:45 pmRNSResult of AGM
24th Oct 20177:00 amRNSAGM Statement
13th Oct 20177:00 amRNSMiddle East Update
29th Sep 20177:04 amRNSFinal Results
29th Sep 20177:01 amRNSNotice of AGM
21st Sep 20174:05 pmRNSHolding(s) in Company
19th Sep 20177:00 amRNSPremaitha to offer NIPT in South Africa
7th Sep 20173:10 pmRNSFurther Patent Infringement Claims
29th Aug 20177:00 amRNSApproved for Good Manufacturing Process in Brazil
18th Jul 20172:02 pmRNSHolding(s) in Company
12th Jul 20177:00 amRNSInvestment Agreement Extension with Thermo Fisher
10th Jul 20177:00 amRNSPremaitha announces two laboratory hub contracts
3rd Jul 20177:00 amRNSLitigation Update
27th Jun 20177:00 amRNSHolding(s) in Company
16th Jun 20177:00 amRNSPremaitha launches Sage NIPT solution
5th Jun 20177:00 amRNSIndia Business Update
26th May 20177:00 amRNSIONA test validation on Thermo Fisher's Ion S5
19th May 20172:30 pmRNSPremaitha welcomes NIPT recommendation in France
16th May 20177:00 amRNSYear End Trading Update
12th May 20172:15 pmRNSUpdate Re. Swiss Customer
3rd Apr 20174:48 pmRNSHolding(s) in Company
31st Mar 20174:00 pmRNSSecond tranche of warrants issued to Thermo Fisher
17th Mar 20177:15 amRNSHardman Research: Expanding global distribution
13th Mar 20177:00 amRNSPremaitha to Attend International Medical Events
2nd Mar 201711:03 amRNSCompletion of Yourgene Acquisition
27th Feb 20177:00 amRNSCompletion of Acquisition
22nd Feb 20179:37 amRNSHolding(s) in Company
20th Feb 20177:00 amRNSMiddle East Business Update
16th Feb 20175:34 pmRNSHolding(s) in Company
15th Feb 20177:00 amRNSIssue of Equity
14th Feb 20179:32 amRNSHolding(s) in Company
13th Feb 20177:00 amRNSNew partnership with European diagnostics group

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.